European Review for Medical and Pharmacological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-05-21 145aa4a9m26暂无昵称来自浙江省

终于被踢咯

70 0

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-03-26 145aa4a9m26暂无昵称来自浙江省

已经 on hold了，马上要被踢了

103 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2023-05-09 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：综合性期刊
经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30
%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教

134 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-03-05 ms7000001027533891 来自安徽省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：临床
经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗

72 0

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2019-12-01 14766288m61暂无昵称

这个文章是不是只有under consideration的状态呀？

152 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2023-10-29 ms4000001373859908 来自北京

请问一下Under consideration会持续多久呢？

122 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2023-11-20 ms4000001373859908 来自北京

偏重的研究方向：生信
经验分享：这个返修后underconsideration要多久？

275 0

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2023-10-20 ms4000001373859908 来自北京

审稿速度:24.0 | 投稿命中率:5.0
偏重的研究方向：生信
经验分享：Under consideration需要多久？

105 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-11-25 ms7000001976046291 来自上海

请问有大佬分享一下这个杂志的endnote格式吗非常感谢

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30 %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：临床 经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信 经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：生信 经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理 经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-02-12 第五先生

偏重的研究方向：临床药理
经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度

159 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务